P
Paul H. P. Groeneveld
Researcher at Leiden University Medical Center
Publications - 20
Citations - 1104
Paul H. P. Groeneveld is an academic researcher from Leiden University Medical Center. The author has contributed to research in topics: Tumor necrosis factor alpha & Peptidoglycan. The author has an hindex of 15, co-authored 20 publications receiving 1036 citations. Previous affiliations of Paul H. P. Groeneveld include Boston Children's Hospital.
Papers
More filters
Journal ArticleDOI
Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: The effect of gender, race, and CYP2B6 polymorphism
David M. Burger,Ilse P. van der Heiden,Charles la Porte,Marchina E. van der Ende,Paul H. P. Groeneveld,Clemens Richter,Peter J. Koopmans,Frank P. Kroon,Herman G. Sprenger,Jan Lindemans,Paul W. Schenk,Ron H.N. van Schaik +11 more
TL;DR: Gender and race are important factors in determining interpatient variability in plasma efavirenz concentrations which were unaffected by the presence of the CYP2B6 C1459T polymorphism.
Journal ArticleDOI
Antibiotic-Induced Release of Lipoteichoic Acid and Peptidoglycan from Staphylococcus aureus: Quantitative Measurements and Biological Reactivities
P. van Langevelde,J. T. Van Dissel,E. Ravensbergen,B. J. Appelmelk,I. A. Schrijver,Paul H. P. Groeneveld +5 more
TL;DR: Enzymatic degradation of PG in the supernatant indicated that PG was mainly responsible for the observed biological reactivity, and the capacity of β-lactam supernatants to stimulate the production of tumor necrosis factor alpha and interleukin-10 in human whole blood was significantly higher than that of protein synthesis inhibitor or controlsupernatants.
Journal ArticleDOI
Declining Hepatitis C Virus (HCV) Incidence in Dutch Human Immunodeficiency Virus-Positive Men Who Have Sex With Men After Unrestricted Access to HCV Therapy
Anne Boerekamps,Guido E.L. van den Berk,F. N. Lauw,Eliane M. S. Leyten,Marjo E. E. van Kasteren,Arne van Eeden,Dirk Posthouwer,Mark A. A. Claassen,Anton S M Dofferhoff,D. W. M. Verhagen,Wouter F W Bierman,Kamilla D. Lettinga,Frank P. Kroon,Corine E Delsing,Paul H. P. Groeneveld,Robert Soetekouw,Edgar J G Peters,Sebastiaan J. Hullegie,Stephanie Popping,David A. M. C. van de Vijver,Charles A. Boucher,Joop E. Arends,Bart J. A. Rijnders +22 more
TL;DR: Unrestricted DAA availability in the Netherlands was followed by a 51% decrease in acute HCV infections among HIV-positive MSM, which contradicts a decrease in risk behavior as an alternative explanation.
Journal ArticleDOI
Effectiveness and cost-effectiveness of a nurse-delivered intervention to improve adherence to treatment for HIV: a pragmatic, multicentre, open-label, randomised clinical trial.
Marijn de Bruin,Marijn de Bruin,E. Oberjé,Wolfgang Viechtbauer,Hans-Erik Nobel,Mickaël Hiligsmann,Cees van Nieuwkoop,Jan Veenstra,Frank J Pijnappel,Frank P. Kroon,Laura van Zonneveld,Paul H. P. Groeneveld,Marjolein van Broekhuizen,Silvia M. A. A. Evers,Jan M. Prins +14 more
TL;DR: AIMS reduced viral load, increased QALYs, and saved resources, and was cost-effective (ie, dominant: cheaper and more effective) since it reduced lifetime societal costs by €592 per patient and increased QalYs by 0·034 per patient.
Journal ArticleDOI
Endotoxin, Cytokines, and Procalcitonin in Febrile Patients Admitted to the Hospital: Identification of Subjects at High Risk of Mortality
Petra van Langevelde,Karin Joop,Jenny van Loon,Marijke Frölich,Paul H. P. Groeneveld,Rudi G. J. Westendorp,Jaap T. van Dissel +6 more
TL;DR: When febrile patients are screened on hospital admission to identify those with a high risk for mortality, clinical judgment on the basis of age, underlying disease, and recent history outweighs the predictive value of endotoxin, cytokine, and procalcitonin levels.